
Obesity poses significant health risks including metabolic complications, cardiovascular disease, and cancer. However, a subgroup of individuals with obesity do not meet diagnostic criteria for overt cardiometabolic disease. These individuals are often described as having obesity without clinically manifest metabolic complications. Despite this apparent clinical profile, obesity may still be associated with systemic alterations in gene expression and molecular pathways. In this exploratory study, we conducted a comprehensive transcriptomic analysis of whole blood samples from individuals with obesity without overt metabolic abnormalities (OBO) and lean healthy controls (LHC) to identify differentially expressed genes (DEGs) and pathway-level differences. Unsupervised dimensionality reduction was used to visualize global transcriptional patterns between groups. Differential expression analysis revealed 106 upregulated and 322 downregulated genes in OBO, with the de-ubiquitinase USP17 family and snoRNAs among the most significantly altered. Pathway enrichment analysis identified 33 differentially enriched pathways, predominantly showing lower inferred enrichment of immune-related and DNA damage/repair-associated gene sets in OBO compared with LHC. These exploratory findings demonstrate that obesity, even in the absence of overt metabolic disease, is associated with distinct whole-blood transcriptomic signatures. The results provide a hypothesis-generating framework for understanding early systemic molecular alterations associated with obesity.
Prader-Willi syndrome (PWS) is a complex multisystemic genetic condition characterized by obesity, short stature and growth with other hormone deficiencies. Aromatase inhibitors (AI) delay estrogen-driven epiphyseal fusion and may enhance near adult height (AH). We investigated whether Anastrozole, a potent aromatase inhibitor, could impact AH in adolescent boys with PWS treated with growth hormone (GH). We undertook a retrospective designed study of two groups of boys diagnosed with PWS at a young age and treated with GH. Eighteen boys treated with GH alone (GHA) were compared to 19 boys treated with GH and AI added between 10 and 13 years of age. Height, weight and bone age were tracked. We analyzed AH achieved in those treated with GH alone (GHA) vs. GH plus AI (GHAI). ANOVA was used for data analysis. More advanced bone age and a higher body mass index were found in both subject groups and a slowdown of skeletal maturation in the treated GHAI group. Mean age after reaching AH for the GHA group was 14.2 years and 17.2 years for the GHAI group. The mean AH standard deviation score (AH-SDS) before and after treatment in the GHA group was -1.8 ± 1.5 /0.11 ± 1.0 and -0.85 ± 0.7/0.81 ± 0.9 for GHAI, both significant (p < 0.0001), and difference between AH-SDS was also significantly greater in the GHAI group [1.01 ± 0.33 (p = 0.004)]. Increased adiposity and premature adrenarche may accelerate growth velocity in PWS children and decreased AH. Anastrozole was effective in slowing bone maturation and improving AH in GH treated adolescents without significant side effects.
To define adrenal imaging phenotypes across primary aldosteronism (PA), low-renin hypertension (LRH), normal-renin hypertension (NRH) and controls. This retrospective study included 196 patients evaluated for suspected PA between January 2024 and February 2025. Plasma aldosterone concentration (PAC) was measured by LC–MS/MS. Diagnosis and subtype evaluation of PA was conducted according to Endocrine Society Guidelines (n=95). Individuals who did not meet predefined criteria for PA were further categorized as LRH (n=59) or NRH (n=42) based on the direct renin concentration and aldosterone-to-renin-ratio. Age- and sex-matched individuals without known hypertension served as controls (n=50). Imaging features on CT and MRI, independently and blindly segmented by two radiologists, were categorized in diffuse adrenal enlargement, micronodules (< 10 mm), adenoma/indeterminate lesions (≥ 10 mm), and nodular hyperplasia. Median age was highest in PA (50.0 years), followed by LRH (48.0), and NRH (44.0) (p = 0.049). Sex distribution showed female predominance in NRH (81.0
Objective Attenuated endogenous secretion of glucagon-like peptide-1 (GLP-1) is a defining feature of type 2 diabetes mellitus (T2DM), yet the precise molecular circuitry underpinning this defect remains obscure. Here, we delineate how METTL14-driven N6-methyladenosine (m6A) marking of the long noncoding RNA (lncRNA) Gm2824 modulates GLP-1 output through the YBX1/Foxa1 signaling cascade.Methods Murine enteroendocrine STC-1 cells were challenged with high-glucose (HG) conditions to emulate the diabetic milieu. Transcriptional abundance and m6A decoration of Gm2824 were quantified via qPCR and MeRIP-qPCR. Molecular engagement between Gm2824, YBX1, and the Foxa1 promoter was interrogated using RNA pull-down, RNA immunoprecipitation (RIP), and dual-luciferase assays. Complementary in vivo analyses employed Gm2824 knockout and knock-in mouse models with experimental T2DM to monitor metabolic homeostasis and incretin signaling dynamics.Results Sustained hyperglycemia suppressed METTL14 expression, leading to diminished m6A modification and compromised stability of Gm2824. This lncRNA physically associates with YBX1, fostering its nuclear import and promoter occupancy at Foxa1, thereby amplifying Foxa1 transcriptional activity. Elevated Foxa1 subsequently drives Pcsk1 expression, augmenting GLP-1 maturation. Ablation of Gm2824 disrupted the YBX1/Foxa1 axis, blunting GLP-1 release and aggravating hyperglycemia. In contrast, enforced Gm2824 expression reinstated GLP-1 biosynthesis and normalized glycemic control in diabetic mice-a rescue effect nullified by YBX1 depletion.Conclusion METTL14-dependent m6A deposition safeguards lncRNA Gm2824 integrity, enabling it to serve as a molecular scaffold that recruits YBX1 to activate Foxa1-mediated GLP-1 generation. Disruption of this epitranscriptomic circuit under hyperglycemic stress contributes to the incretin insufficiency characteristic of T2DM.